CAMBRIDGE, Mass. (AP) -- Ariad Pharmaceuticals Inc. said Tuesday that European Union regulators approved the marketing of its leukemia pill Iclusig.
Iclusig was approved for use against treatment-resistant chronic myeloid leukemia and for patients with acute lymphoblastic leukemia with a type of chromosome abnormality.
The Food and Drug Administration approved Iclusig in December as a treatment for both of those conditions.
Shares of Ariad lost 8 cents to $19.45 in afternoon trading.